{"title":"重组人生长激素治疗生长激素缺乏症的临床观察","authors":"Chun-ya Ni","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency and its effect on thyroid function. \n \n \nMethods \nFrom June 2016 to June 2018, 81 children with growth hormone deficiency in Da Jiangdong Hospital of Hangzhou were selected.The rhGH was given 1 time before bedtime, and the treatment course was 6 months.The growth and development, bone metabolism and thyroid function were compared before treatment, 3 months and 6 months after treatment. \n \n \nResults \nThe height and growth rate at 3 months after treatment [(131.76±2.28)cm, (10.40±0.87)cm/year] and at 6 months after treatment [(134.83)cm, (11.74±0.72)cm/year] were higher than those before treatment [(127.32±3.49)cm, (4.32±1.08)cm/year] (F=7.973, P=0.000, F=12.314, P=0.000), which at 6 months after treatment were higher than those 3 months after treatment (height: t=9.586, 16.405, growth rate: t=39.457, 51.448, P=0.000). There was no statistically significant difference in BMI among before treatment [(17.21±4.28)kg/m2], 3 months after treatment [(17.86±5.14)kg/m2] and 6 months after treatment [(18.01±4.35)kg/m2] (F=0.762, P=0.391). The serum levels of BGP and ALP at 3 months after treatment [(7.19±0.38)ng/mL, (129.34±8.97)U/L] and at 6 months after treatment [(7.94±0.63)ng/mL, (154.67±10.42)U/L] were higher than those before treatment [(6.38±0.57)ng/mL, (108.49±6.51)U/L] (F=8.971, P=0.000, F=15.427, P=0.000), and the levels of BGP and ALP at 6 months after treatment were higher than those 3 months after treatment (t=9.175, P=0.000, t=16.581, P=0.000). There were no statistically significant differences in serum FT3, TSH and FT4 levels before treatment, 3 months after treatment and 6 months after treatment (F=0.893, P=0.287, F=0.472, P=0.517, F=1.084, P=0213). \n \n \nConclusion \nrhGH has significant clinical effects on children with growth hormone deficiency, and has no significant effect on thyroid function, which is worthy of clinical reference. \n \n \nKey words: \nGrowth disorders; Human growth hormone; Thyroid function tests","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"546-549"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical observation of recombinant human growth hormone in the treatment of growth hormone deficiency\",\"authors\":\"Chun-ya Ni\",\"doi\":\"10.3760/CMA.J.ISSN.1008-6706.2020.05.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency and its effect on thyroid function. \\n \\n \\nMethods \\nFrom June 2016 to June 2018, 81 children with growth hormone deficiency in Da Jiangdong Hospital of Hangzhou were selected.The rhGH was given 1 time before bedtime, and the treatment course was 6 months.The growth and development, bone metabolism and thyroid function were compared before treatment, 3 months and 6 months after treatment. \\n \\n \\nResults \\nThe height and growth rate at 3 months after treatment [(131.76±2.28)cm, (10.40±0.87)cm/year] and at 6 months after treatment [(134.83)cm, (11.74±0.72)cm/year] were higher than those before treatment [(127.32±3.49)cm, (4.32±1.08)cm/year] (F=7.973, P=0.000, F=12.314, P=0.000), which at 6 months after treatment were higher than those 3 months after treatment (height: t=9.586, 16.405, growth rate: t=39.457, 51.448, P=0.000). There was no statistically significant difference in BMI among before treatment [(17.21±4.28)kg/m2], 3 months after treatment [(17.86±5.14)kg/m2] and 6 months after treatment [(18.01±4.35)kg/m2] (F=0.762, P=0.391). The serum levels of BGP and ALP at 3 months after treatment [(7.19±0.38)ng/mL, (129.34±8.97)U/L] and at 6 months after treatment [(7.94±0.63)ng/mL, (154.67±10.42)U/L] were higher than those before treatment [(6.38±0.57)ng/mL, (108.49±6.51)U/L] (F=8.971, P=0.000, F=15.427, P=0.000), and the levels of BGP and ALP at 6 months after treatment were higher than those 3 months after treatment (t=9.175, P=0.000, t=16.581, P=0.000). There were no statistically significant differences in serum FT3, TSH and FT4 levels before treatment, 3 months after treatment and 6 months after treatment (F=0.893, P=0.287, F=0.472, P=0.517, F=1.084, P=0213). \\n \\n \\nConclusion \\nrhGH has significant clinical effects on children with growth hormone deficiency, and has no significant effect on thyroid function, which is worthy of clinical reference. \\n \\n \\nKey words: \\nGrowth disorders; Human growth hormone; Thyroid function tests\",\"PeriodicalId\":10226,\"journal\":{\"name\":\"中国基层医药\",\"volume\":\"27 1\",\"pages\":\"546-549\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国基层医药\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical observation of recombinant human growth hormone in the treatment of growth hormone deficiency
Objective
To investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency and its effect on thyroid function.
Methods
From June 2016 to June 2018, 81 children with growth hormone deficiency in Da Jiangdong Hospital of Hangzhou were selected.The rhGH was given 1 time before bedtime, and the treatment course was 6 months.The growth and development, bone metabolism and thyroid function were compared before treatment, 3 months and 6 months after treatment.
Results
The height and growth rate at 3 months after treatment [(131.76±2.28)cm, (10.40±0.87)cm/year] and at 6 months after treatment [(134.83)cm, (11.74±0.72)cm/year] were higher than those before treatment [(127.32±3.49)cm, (4.32±1.08)cm/year] (F=7.973, P=0.000, F=12.314, P=0.000), which at 6 months after treatment were higher than those 3 months after treatment (height: t=9.586, 16.405, growth rate: t=39.457, 51.448, P=0.000). There was no statistically significant difference in BMI among before treatment [(17.21±4.28)kg/m2], 3 months after treatment [(17.86±5.14)kg/m2] and 6 months after treatment [(18.01±4.35)kg/m2] (F=0.762, P=0.391). The serum levels of BGP and ALP at 3 months after treatment [(7.19±0.38)ng/mL, (129.34±8.97)U/L] and at 6 months after treatment [(7.94±0.63)ng/mL, (154.67±10.42)U/L] were higher than those before treatment [(6.38±0.57)ng/mL, (108.49±6.51)U/L] (F=8.971, P=0.000, F=15.427, P=0.000), and the levels of BGP and ALP at 6 months after treatment were higher than those 3 months after treatment (t=9.175, P=0.000, t=16.581, P=0.000). There were no statistically significant differences in serum FT3, TSH and FT4 levels before treatment, 3 months after treatment and 6 months after treatment (F=0.893, P=0.287, F=0.472, P=0.517, F=1.084, P=0213).
Conclusion
rhGH has significant clinical effects on children with growth hormone deficiency, and has no significant effect on thyroid function, which is worthy of clinical reference.
Key words:
Growth disorders; Human growth hormone; Thyroid function tests
期刊介绍:
Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.